Subconjunctival triamcinolone acetonide in the management of ocular inflammatory disease
Subconjunctival triamcinolone acetonide in the management of ocular inflammatory disease
Purpose: To review the existing evidence that supports the subconjunctival use of triamcinolone acetonide (TA) in the treatment of various ophthalmic diseases.
Methods: A literature search was performed for published articles about the pharmacokinetic (PK) and pharmacodynamic characteristics of triamcinolone, as well as its potential ophthalmic use, focused mainly in the subconjunctival mode of delivery. Search terms included corticosteroids, triamcinolone, ocular, subconjunctival, and ophthalmic.
Results: Corticosteroids represent the mainstay of treatment of ocular inflammation, exerting their action by affecting multiple pathways of the inflammatory response, making them particularly effective in the majority of cases. However, due to the number and severity of the side effects associated with their use, they have to be given with caution. Corticosteroids can be given topically, subconjunctivally, intraocularly, and systemically to treat a variety of ocular diseases with specific pharmacological and PK characteristics. Triamcinolone is one of the most widely used corticosteroids in the treatment of ocular inflammation. This glucocorticoid used subconjunctivally was proven to be particularly safe and effective in some common and important inflammatory ophthalmic diseases such as anterior scleritis, uveitis, and corneal graft rejection. Further, there are other indications for its successful use where data exist, but somehow less abundant.
Conclusions: This article highlights the potential of TA to complement the treatment armamentarium of anterior segment inflammation.
Athanasiadis, Y.
8e82f4d7-361c-4a2c-99fe-9de0852e1bad
Tsatos, M.
a84f1164-a747-4c04-a190-67d84a65623b
Sharma, A.
144dd2e6-ea28-43dd-a4d1-c6fa3115fc63
Hossain, Parwez
563de5fc-84ad-4539-9228-bde0237eaf51
Athanasiadis, Y.
8e82f4d7-361c-4a2c-99fe-9de0852e1bad
Tsatos, M.
a84f1164-a747-4c04-a190-67d84a65623b
Sharma, A.
144dd2e6-ea28-43dd-a4d1-c6fa3115fc63
Hossain, Parwez
563de5fc-84ad-4539-9228-bde0237eaf51
Athanasiadis, Y., Tsatos, M., Sharma, A. and Hossain, Parwez
(2013)
Subconjunctival triamcinolone acetonide in the management of ocular inflammatory disease.
Journal of Ocular Pharmacology and Therapeutics.
(doi:10.1089/jop.2012.0208).
(PMID:23485045)
Abstract
Purpose: To review the existing evidence that supports the subconjunctival use of triamcinolone acetonide (TA) in the treatment of various ophthalmic diseases.
Methods: A literature search was performed for published articles about the pharmacokinetic (PK) and pharmacodynamic characteristics of triamcinolone, as well as its potential ophthalmic use, focused mainly in the subconjunctival mode of delivery. Search terms included corticosteroids, triamcinolone, ocular, subconjunctival, and ophthalmic.
Results: Corticosteroids represent the mainstay of treatment of ocular inflammation, exerting their action by affecting multiple pathways of the inflammatory response, making them particularly effective in the majority of cases. However, due to the number and severity of the side effects associated with their use, they have to be given with caution. Corticosteroids can be given topically, subconjunctivally, intraocularly, and systemically to treat a variety of ocular diseases with specific pharmacological and PK characteristics. Triamcinolone is one of the most widely used corticosteroids in the treatment of ocular inflammation. This glucocorticoid used subconjunctivally was proven to be particularly safe and effective in some common and important inflammatory ophthalmic diseases such as anterior scleritis, uveitis, and corneal graft rejection. Further, there are other indications for its successful use where data exist, but somehow less abundant.
Conclusions: This article highlights the potential of TA to complement the treatment armamentarium of anterior segment inflammation.
This record has no associated files available for download.
More information
e-pub ahead of print date: 13 March 2013
Organisations:
Clinical & Experimental Sciences
Identifiers
Local EPrints ID: 352123
URI: http://eprints.soton.ac.uk/id/eprint/352123
ISSN: 1080-7683
PURE UUID: f9db12ef-d5fd-4ef0-8c6b-943649bff20a
Catalogue record
Date deposited: 07 May 2013 10:51
Last modified: 15 Mar 2024 03:24
Export record
Altmetrics
Contributors
Author:
Y. Athanasiadis
Author:
M. Tsatos
Author:
A. Sharma
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
